Ivermectin Stada Arzneimittel Ag

Ivermectin, the active ingredient in Ivermectin Stada Arzneimittel Ag, is an antiparasitic (macrocyclic lactone) presented as an oral formulation for systemic use. It is employed to treat a range of helminth and ectoparasite infections in humans, including river blindness, strongyloidiasis, scabies and lice infestations.

GNH USA supplies Ivermectin Stada Arzneimittel Ag as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured batches, regulatory compliance and reliable logistics for global health programmes and emergency response initiatives.

Ivermectin is an antiparasitic agent used to treat several helminthic and ectoparasitic infections. - Onchocerciasis (river blindness): eliminates microfilariae, reducing skin and ocular disease. - Strongyloidiasis: eradicates intestinal Strongyloides stercoralis infection. - Scabies: kills Sarcoptes scabiei mites, relieving itching and skin lesions. - Pediculosis (lice infestation): destroys head and body lice, preventing reinfestation. - Other helminth infections: treats various nematode infections as indicated by clinical guidelines.

Ivermectin may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild stomach upset or queasiness. - Diarrhea: loose stools, usually self‑limiting. - Dizziness: transient light‑headedness or vertigo. - Pruritus: itching at the site of parasite death. - Abdominal pain: cramp‑like discomfort in the abdomen. - Fatigue: feeling unusually tired or weak.

Serious or Rare Side Effects: - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Neurological events: seizures, encephalopathy or altered consciousness. - Hepatotoxicity: elevated liver enzymes or jaundice. - Hypotension: sudden drop in blood pressure, potentially leading to fainting.

When prescribing ivermectin, clinicians should consider several precautionary measures to ensure safe use. - Indication verification: confirm the infection type and severity before initiating therapy. - Concomitant medications: review patient’s current drugs for potential interactions, especially with CYP3A4 modulators. - Hepatic function: assess liver function, as impaired metabolism may increase drug exposure. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks, due to limited safety data. - Pediatric use: adjust dosing carefully and monitor for adverse reactions in children. - Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Ivermectin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers: drugs such as rifampicin or carbamazepine may markedly reduce ivermectin plasma levels. - P‑glycoprotein inhibitors: co‑administration with verapamil or quinidine can increase ivermectin exposure and risk of toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor INR or clotting parameters as ivermectin may potentiate bleeding risk. - CNS depressants: concurrent use with barbiturates or benzodiazepines may enhance central nervous system effects. - Immunosuppressants: observe for altered parasite clearance when combined with agents like corticosteroids.